evodiamine has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Liao, J; Lu, Q; Niu, C; Wang, H; Wang, S; Yu, Y | 1 |
| Kontani, Y; Kusudo, T; Mori, N; Okamatsu, Y; Saito, M; Takeuchi, T; Wang, T; Yamashita, H; Yamashita, Y | 1 |
2 other study(ies) available for evodiamine and Alloxan Diabetes
| Article | Year |
|---|---|
Serum untargeted metabolomics analysis of the mechanisms of evodiamine on type 2 diabetes mellitus model rats.
Topics: Amino Sugars; Animals; Arginine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Metabolomics; Nucleotides; Proline; Quinazolines; Rats; Streptozocin; Tryptophan | 2022 |
Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Evodia; Female; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Obese; Phosphorylation; Quinazolines; Ribosomal Protein S6 Kinases; Serine; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |